Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Raises Stake in Ibis Biosciences by $20M; Retains Right to Buy

NEW YORK (GenomeWeb News) – Abbott has invested a second $20 million in pathogen detection developer Ibis Biosciences, upping its stake in the company to 18.6 percent, Ibis parent firm Isis Pharmaceuticals said today.
The agreement follows a $20 million investment that Abbott made in January that gave it a 10.25 percent stake in the firm.
Ibis plans to use the cash to develop its T5000 Biosensor System, a system for rapidly identifying and characterizing infectious agents, including pandemic diseases, emerging or previously unknown pathogens, and hospital-acquired infections.
Abbott retains the exclusive option to purchase the remaining equity in Ibis for an additional $175 million to $190 million through June 30, 2009.
If Abbott purchases Ibis, it will owe Isis earn-out money related to certain sales.
"We are aggressively accelerating the expansion of our commercial products into larger market opportunities, and this recent financing from Abbott will provide the capital to continue on this path," said Ibis president Michael Treble in a statement.
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.